Svb Leerink Brokers Lower Earnings Estimates for Mallinckrodt PLC (MNK) Posted by Scott Davis on May 11th, 2019
Mallinckrodt PLC (NYSE:MNK) – Stock analysts at Svb Leerink lowered their Q2 2019 earnings per share (EPS) estimates for Mallinckrodt in a research note issued to investors on Tuesday, May 7th. Svb Leerink analyst A. Fadia now anticipates that the company will post earnings of $2.21 per share for the quarter, down from their prior estimate of $2.23. Svb Leerink also issued estimates for Mallinckrodt’s Q3 2019 earnings at $2.17 EPS, Q4 2019 earnings at $2.13 EPS and FY2022 earnings at $4.64 EPS. Get Mallinckrodt alerts:
Other equities analysts have also recently issued reports about the stock. Canaccord Genuity set a $40.00 target price on shares of Mallinckrodt and gave the company a “buy” rating in a research note on Monday, March 18th. Mizuho upped their target price on shares of Mallinckrodt to $26.00 and gave the company a “neutral” rating in a research note on Thursday, February 28th. ValuEngine upgraded shares of Mallinckrodt from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. SunTrust Banks started coverage on shares of Mallinckrodt in a research note on Tuesday, March 19th. They set a “hold” rating and a $23.00 target price for the company. Finally, Morgan Stanley set a $32.00 price target on shares of Mallinckrodt and gave the company a “hold” rating in a report on Thursday, February 28th. Four research analysts have rated the stock with a sell rating, nine have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $30.88. NYSE:MNK opened at $16.29 on Friday. The firm has a market cap of $1.37 billion, a P/E ratio of 2.03, a P/E/G ratio of 0.16 and a beta of 2.12. Mallinckrodt has a one year low of $13.45 and a one year high of $36.65. The company has a quick ratio of 1.17, a current ratio of 1.51 and a debt-to-equity ratio of 2.10.
Mallinckrodt (NYSE:MNK) last released its earnings results on Tuesday, May 7th. The company reported $1.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.73 by $0.21. The firm had revenue of $791.00 million during the quarter, compared to analysts’ expectations of $766.27 million. Mallinckrodt had a negative net margin of 134.63% and a positive return on equity of 11.14%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.31 EPS.
A number of institutional investors have recently made changes to their positions in MNK. CWM LLC increased its holdings in Mallinckrodt by 222.8% in the 1st quarter. CWM LLC now owns 1,159 shares of the company’s stock valued at $25,000 after buying an additional 800 shares during the period. Oregon Public Employees Retirement Fund increased its holdings in Mallinckrodt by 1,480.0% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 520,326 shares of the company’s stock valued at $33,000 after buying an additional 487,394 shares during the period. FNY Investment Advisers LLC increased its holdings in Mallinckrodt by 210.4% in the 4th quarter. FNY Investment Advisers LLC now owns 2,288 shares of the company’s stock valued at $36,000 after buying an additional 1,551 shares during the period. We Are One Seven LLC bought a new stake in Mallinckrodt in the 4th quarter valued at $38,000. Finally, QS Investors LLC increased its holdings in Mallinckrodt by 14.3% in the 4th quarter. QS Investors LLC now owns 4,000 shares of the company’s stock valued at $64,000 after buying an additional 500 shares during the period.
About Mallinckrodt
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.
